Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.45 |
| ▸ | NRAS | P01111 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12553680 | 0.87 | FLT3 (0.42) | FLT3NRASIRAK4IRAK1PRMT5 | |
| SCHEMBL10238381 | 0.86 | IRAK4 (0.40) | FLT3NRASIRAK4IRAK1PRMT5 | |
| SCHEMBL10239830 | 0.85 | FLT3 (0.59) | FLT3NRASIRAK4IRAK1 | |
| SCHEMBL10239867 | 0.85 | FLT3 (0.47) | FLT3NRASIRAK4 | |
| SCHEMBL12553533 | 0.83 | IRAK4 (0.55) | FLT3NRASIRAK4IRAK1 | |
| SCHEMBL12553544 | 0.83 | FLT3 (0.44) | FLT3NRASIRAK4IRAK1PRMT5 | |
| SCHEMBL12553501 | 0.82 | FLT3 (0.38) | FLT3NRASIRAK4IRAK1PRMT5 | |
| SCHEMBL376866 | 0.82 | IRAK4 (0.59) | FLT3NRASIRAK4IRAK1 | |
| SCHEMBL376467 | 0.82 | IRAK4 (0.58) | FLT3IRAK4 | |
| SCHEMBL376466 | 0.82 | IRAK4 (0.58) | FLT3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | FLT3 496/4885NRAS 1025/4885IRAK4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.